Titan Biotech Limited has officially announced the results of its postal ballot process, confirming overwhelming shareholder approval for the proposed 1:5 stock split and memorandum of association alteration. The company submitted the voting results to BSE on December 31, 2025, following the conclusion of remote e-voting on December 30, 2025.

Official Postal Ballot Results

The postal ballot process demonstrated exceptional shareholder support across both resolutions, with the scrutinizer's report confirming the requisite majority:

Corporate Action Details

The approved resolutions encompass two key corporate actions that will reshape the company's equity structure:

Shareholder Category Performance

The voting pattern revealed strong consensus across all shareholder categories:

Promoter and Promoter Group:

• Total Holding: 4,609,525 shares
• Participation Rate: 99.9995%
• Approval Rate: 100% for both resolutions

Public Non-Institutional Shareholders:

• Total Holding: 3,654,175 shares
• Participation Rate: 0.18%
• Approval Rate: Over 99% for both resolutions

Regulatory Compliance Framework

The postal ballot was conducted under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Charanjit Singh submitted the comprehensive voting results and scrutinizer's report to BSE, confirming that both ordinary resolutions were deemed passed on December 30, 2025.

Implementation Timeline

With formal approval secured and regulatory submissions completed, the stock split implementation will proceed according to the previously announced timeline. The subdivision will convert each existing equity share of face value ₹10.00 into five equity shares of face value ₹2.00 each, enhancing liquidity and accessibility for retail investors in the pharmaceutical sector.

The comprehensive voting results and scrutinizer's report are available on the company's website at www.titanbiotechltd.com , providing complete transparency for all stakeholders regarding this significant corporate restructuring initiative.

Titan Biotech Limited , a key player in the biotechnology sector, has announced strong financial results for the second quarter ended September 30, 2025, showcasing significant growth in both revenue and profitability.

Financial Highlights

The company reported a substantial increase in its revenue from operations, which stood at Rs. 5,679.20 lakhs for Q2 FY2026, compared to Rs. 4,721.86 lakhs in the previous quarter, marking a robust growth of 20.27%. This impressive top-line performance underscores Titan Biotech's strong market position and growing demand for its products.

Profitability also saw a notable improvement, with net profit for the quarter reaching Rs. 686.25 lakhs, up from Rs. 616.08 lakhs in the prior quarter, representing an 11.39% increase. This growth in profitability reflects the company's effective cost management and operational efficiency.

Half-Yearly Performance

For the six-month period ending September 30, 2025, Titan Biotech's revenue reached Rs. 10,401.06 lakhs, compared to Rs. 9,715.64 lakhs in the same period last year, indicating a year-on-year growth of 7.05%. This consistent performance over the first half of the fiscal year demonstrates the company's resilience and ability to maintain growth momentum.

Earnings Per Share

The company's earnings per share (EPS) for Q2 FY2026 stood at Rs. 8.30, a significant increase from Rs. 7.46 in the previous quarter. This 11.26% growth in EPS is likely to be well-received by investors, as it indicates improved returns on their investments.

Management Approval

The Board of Directors of Titan Biotech Limited approved both standalone and consolidated unaudited financial results at their meeting held on November 11, 2025. This approval underscores the management's confidence in the company's financial performance and reporting standards.

Consolidated Performance

On a consolidated basis, Titan Biotech Limited, along with its associates Peptech Biosciences Limited and Titan Media Limited, demonstrated strong financial results. The consolidated revenue from operations for Q2 FY2026 was Rs. 5,435.47 lakhs, with a total income of Rs. 5,567.92 lakhs.

The consolidated profit before tax for the quarter stood at Rs. 921.86 lakhs, while the profit after tax reached Rs. 776.47 lakhs, including the share of profit from associates.

Balance Sheet Strength

As of September 30, 2025, Titan Biotech's consolidated balance sheet showed total assets of Rs. 20,248.60 lakhs, up from Rs. 17,470.75 lakhs as of March 31, 2025. The company's equity position remained strong, with total equity increasing to Rs. 16,641.45 lakhs from Rs. 15,340.32 lakhs at the end of the previous fiscal year.

Cash Flow and Liquidity

The company maintained a healthy cash position, with cash and cash equivalents of Rs. 163.27 lakhs as of September 30, 2025. The net cash generated from operating activities for the six-month period was robust, indicating strong operational cash flows.

Conclusion

Titan Biotech Limited's Q2 FY2026 results reflect a company on a strong growth trajectory, with impressive revenue growth, improved profitability, and a solid balance sheet. The consistent performance across both standalone and consolidated figures suggests that the company's core operations and its associates are contributing positively to its overall financial health.